Articles

  • Dr. med. Christian Pohlkamp
    from 21.04.2021
    MLL findings portal: Here you can view your findings online

    The daily work of physicians, scientists and MTLA is becoming increasingly digital. A transmission of findings via fax can barely be combined with modern and innovative work processes any mores. For more than a year now, the web-based Findings Portal of the MLL has been used extensively and increasingly for submitting findings, whereby all the findings are then available for download as PDF documents. We would like to introduce this portal to you in this article.

    Post review
    Read article
  • Dr. rer. nat. Christine Käppel
    from 24.02.2021
    An ISO 14001 certified environmental management system for sustainable and environmentally friendly leukemia diagnostics

    As a highly innovative company, we are well aware of the responsibility we bear for creating the world of tomorrow. With this in mind, we have successfully established an ISO 14001 based professional environmental management system in all of our sections and processes. In one assessment, our efforts were verified by the neutral and accredited certification body DEKRA (see ISO 14001 certificate).

    Post review
    Read article
  • Dr. med. Christian Dornes
    from 24.02.2021
    Presentation: The MHP Munich Hematology Practice

    The MLL Munich Leukemia Laboratory is generally associated with specialist hematological diagnostics and innovation. The MHP Munich Hematology Practice is another organ which is involved in insurance-funded and private medical care of patients in the Munich metropolitan area. In this article we would like to introduce you to MHP.

    Post review
    Read article
  • Sarah Kurz
    from 01.02.2021
    New iniative: Genomics for Next Generation Healthcare in Haematological Diseases

    The consortium of GenoMed4All - Genomics and Personalised Medicine for all through Artificial Intelligence in Haematological Diseases is pleased to announce the launch of an ambitious joint initiative selected and granted by the European Commission under the Horizon 2020 Research & Innovation programme. The MLL Munich Leukemia Laboratory is also part of this initiative.

    Post review
    Read article
  • Prof. Dr. med. Dr. phil. Torsten Haferlach
    from 16.12.2020
    The MLL says Thank You

    This very different year is coming to an end. We all had to realize, professionally and privately, that plans and goals are only relative. Furthermore, it became clear how centrally "medicine" can influence our daily lives and actions. We as MLL would like to look back and forward and thank you for the trust you have placed in us and for your cooperation.

    Post review
    Read article
  • Sarah Kurz
    from 11.12.2020
    The MLL Munich Leukemia Laboratory belongs to BAVARIA'S BEST 50

    It is now official: As of this year, the MLL Munich Leukemia Laboratory is one of the 50 fastest-growing medium-sized companies in Bavaria. In recent years, the company has been able to increase its sales and the number of its employees at an above-average rate. In recognition of this achievement, MLL was awarded the BAVARIA'S BEST 50 prize by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy (STMWI) and the Deputy Bavarian Prime Minister Hubert Aiwanger.

    Post review
    Read article
  • Sarah Kurz
    from 25.11.2020
    Torsten Haferlach Leukemia Diagnostics Foundation and Illumina donate sequencing equipment to Latin American laboratories

    "It is time for us to come together to tackle the important tasks in patient care and to make the best possible use of global advances in technology for our patients", says MLL founder and CEO Prof. Dr. Dr. Torsten Haferlach. That is why his foundation, the Torsten Haferlach Leukemia Diagnostics Foundation, together with Illumina, is donating sex iSeq™ instruments to reference laboratories in Latin America so that low to middle-income countries can also advance AML diagnosis and therapy.

    Post review
    Read article
  • Sarah Kurz
    from 18.11.2020
    The MLL Munich Leukemia Laboratory: a portrait

    „When a sample arrives at the MLL, it enters a world of extensive automation and digitization”, writes Leah Lawrence in the Clinical News of the American Society of Hematology (ASH). With an innovative spirit of the times and state-of-the-art methods such as artificial intelligence, the team around Prof. Dr. Claudia Haferlach, Prof. Dr. Dr. Torsten Haferlach and Prof. Dr. Wolfgang Kern works every day to advance leukemia diagnostics in order to provide patients worldwide with the best possible therapy. Now ASH has interviewed the MLL heads and presents the MLL Munich Leukemia Laboratory in its Clinical News.

    Post review
    Read article
  • Dr. med. Christian Pohlkamp
    from 30.09.2020
    On our own behalf: Optimizing the quality of service

    It is our job to offer you the current repertoire of state-of-the-art leukemia diagnostic services in the Munich Leukemia Laboratory (MLL). To fully optimize the diagnostic process, the integrity of the sample collected is of great importance, both to provide reliable test results and to apply the requisite methods within the operating workflow. So that we may always be able to best serve you as the sender of the sample and the affected patients, we would like to explain some important aspects of the pre-analytical phase, which includes blood and bone marrow sample collection, handling and transport to the laboratory.

    Post review
    Read article
  • Prof. Dr. med. Dr. phil. Torsten Haferlach
    from 18.08.2020
    15 Years of MLL Munich Leukemia Laboratory: an anniversary without celebrations

    We opened the MLL on August 1, 2005. The number of samples at the MLL and the possibilities for diagnostic methods have developed in parallel with hematology in the last 15 years. Diagnostics with all its possibilities and needs is becoming more and more exciting for us. It is growing in importance for patients and attending physicians. This is true regarding the description of the disease and its risk profile during diagnosis, as well as to the analyses of the course of the disease, whose numbers have increased sharply, which contribute to therapy management. The total number of samples sent to the MLL in the last 15 years is now over 750,000.

    Post review
    Read article
  • Dr. rer. nat. Manja Meggendorfer, MBA
    from 14.08.2020
    MLL Dx – the new website is live

    The MLL Munich Leukemia Laboratory has been providing comprehensive diagnostics for leukemia and lymphoma patients in our health system for 15 years. Molecular genetics has been an increasingly important component. The demand for comprehensive diagnostics, including from neighboring countries, is rising. Why not also offer this service outside the German health system? The three managing directors asked this question before the idea of establishing MLL Dx – MLL diagnostics – took shape. MLL Dx was founded as an affiliate of MLL in 2018 and has been visible through its own web site since July 2020.

    Post review
    Read article
  • Prof. Dr. med. Dr. phil. Torsten Haferlach
    from 08.06.2020
    Leukemia diagnostics during the pandemic

    In the past few months, we have all been confronted with an entirely new situation. Our patients belong to the high-risk group by definition. Hospitals, outpatient clinics, and medical practices have had to be restructured and reorganize their priorities. Workflows had to be re-examined with regard to factual and time-related aspects with hygiene in mind. The goal has been to ensure continued care for patients, while at the same time protecting the employees trained for that very purpose.

    Post review
    Read article
  • Niroshan Nadarajah
    from 07.06.2020
    MLL uses AWS Cloud Computing infrastructure for NGS data

    Thanks to the rapid advancement of sequencing technology, it has become easier to read an increasingly large amount of DNA. However, the ability to interpret this data has not grown by the same amount. For this purpose, high-performance computer clusters are necessary in order to analyze the large quantities of data for a standard next-generation sequencing (NGS) run. After the initial positive experiences with cloud computing as part of the 5.000 genome projekt, we decided to switch to cloud computing for the evaluation of the NGS routine diagnostics data as well.

    Post review
    Read article
  • Niroshan Nadarajah
    from 20.12.2019
    MLL Academy – Workshop on Next-Generation Sequencing

    The “MLL Academy - Workshop on Next-Generation Sequencing (NGS)” was held for the first time from November 7 - 8, 2019. The eighteen international participants were able to gain detailed insights into the theoretical and practical principals of all individual NGS steps – from generating a library to sequencing to interpreting the data.

    Post review
    Read article
  • Dr. med. Christian Pohlkamp
    from 20.12.2019
    Munich Leukemia Laboratory Developing a Digital Order Entry Platform

    In this digital age, MLL has now set up a way to enter orders online. Following an extensive beta testing phase in the outpatient area, it is now possible to use a corresponding digital platform free of charge.

    Post review
    Read article
  • Prof. Dr. med. Dr. phil. Torsten Haferlach
    from 20.12.2019
    Successful Participation by MLL in the ASH Conference in Orlando

    This year as well, several MLL scientists took advantage of the ASH (American Society of Hematology) in Orlando to get an overview of the current research emphases and future developments. They also gave a number of lectures there and presented a large number of posters.

    Post review
    Read article
  • Dr. med. Christian Pohlkamp
    from 18.11.2019
    MLL develops an interactive PDF version of the test request form.

    Our understanding of the genetic changes underpinning malignant disease has expanded tremendously in the past few years. This is also reflected in the increasingly complex diagnostics on offer, particularly in the field of molecular genetics.

    Post review
    Read article
  • Dr. rer. nat. Christine Käppel
    from 23.10.2019
    Successful Re-Accreditation of MLL

    Since 2009, MLL has been accredited according to the international standards DIN EN ISO 15189 "Medical laboratories - Requirements for quality and competence" and DIN EN ISO/IEC 17025 "General requirements for the competence of testing and calibration laboratories" by the Deutsche Akkreditierungsstelle (DAkkS). In April this year, MLL was once again audited by DAkkS. Its existing accreditations were successfully upheld and expanded with new analyses.

    Post review
    Read article
  • Dr. med. Christian Pohlkamp
    from 03.10.2019
    Helping to advance diagnostics. The role of the physician at the MLL.

    The role of the MLL hematologist involves much more than traditional laboratory tasks. Daily occupation with diagnosing exciting cases from the area of hematological diseases guarantees variety and – at the same time – a closeness to routine clinical practice.

    Post review
    Read article
  • Sarah Kurz
    from 17.09.2019
    Sports for a good cause: That is what Move4Life 2019 was.

    Three races, six workshops, many highlights: The Move4Life benefit event on behalf of the Torsten Haferlach Leukemia Diagnostics Foundation was held on Saturday, 9/14/2019.

    Post review
    Read article
  • from 01.07.2019
    Award: MLL Münchner Leukämielabor GmbH now in the TOP 100

    At the 26th TOP 100 innovation competition, MLL Münchner Leukämielabor GmbH managed to secure a place among the top 100 companies. For this reason, the company was given an award by competition mentor Ranga Yogeshwar, scientific director for the comparison Prof. Dr. Nikolaus Franke, and compamedia on June 28 in the Frankfurt Jahrhunderthalle.

    Post review
    Read article
  • Dr. rer. nat. Ines Schmidts
    from 03.05.2019
    MLL Academy

    The MLL Academy took place for the second time from April 8, 2019 to April 12, 2019. The twelve international participants were able to gain a detailed overview of clinical cases and in particular the special diagnostics of hematological diseases. Due to the positive feedback of participants once again this year, a five-day MLL Academy is already in the works for 2020.

    Post review
    Read article
  • from 04.03.2019
    Cutting-edge and innovative - MLL unveils its very own conference facility

    Since May 2018, the Munich leukemia laboratory has been featuring its very own conference facility covering an area of 500 sqm.  It has a bright and spacious foyer, providing a space for receptions and events of all kinds.

    Post review
    Read article